Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …
D van der Heijde, JCC Wei, M Dougados, P Mease… - The Lancet, 2018 - thelancet.com
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …
Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects
K Matsumoto, S Miyake, M Yano, Y Ueki… - Diabetes …, 1997 - Am Diabetes Assoc
OBJECTIVE To investigate the relative contributions of insulin secretion and insulin
resistance to the development of glucose intolerance in Japanese subjects. RESEARCH …
resistance to the development of glucose intolerance in Japanese subjects. RESEARCH …
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …
[PDF][PDF] Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis
A Ogata, K Tanimura, T Sugimoto, H Inoue… - Arthritis care & …, 2014 - Wiley Online Library
Objective To evaluate the efficacious noninferiority of subcutaneous tocilizumab injection
(TCZ‐SC) monotherapy to intravenous TCZ infusion (TCZ‐IV) monotherapy in Japanese …
(TCZ‐SC) monotherapy to intravenous TCZ infusion (TCZ‐IV) monotherapy in Japanese …
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
N Nishimoto, K Amano, Y Hirabayashi… - Modern …, 2014 - Taylor & Francis
Objectives To investigate the duration of remission and low disease activity (LDA) after
cessation of tocilizumab (TCZ) treatment in rheumatoid arthritis patients who showed …
cessation of tocilizumab (TCZ) treatment in rheumatoid arthritis patients who showed …
Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
S Mori, Y Ueki, N Hirakata, M Oribe, T Hidaka… - Annals of the rheumatic …, 2012 - ard.bmj.com
Objectives We assessed the influence of tocilizumab (TCZ), a humanised monoclonal anti-
interleukin-6 receptor antibody, on antibody response following influenza vaccination in …
interleukin-6 receptor antibody, on antibody response following influenza vaccination in …
Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
S Kawashiri, A Kawakami, S Yamasaki… - Rheumatology …, 2011 - Springer
We investigated the effects of anti-IL-6 receptor antibody, tocilizumab (TCZ), on lipid
metabolism. Nineteen patients with rheumatoid arthritis (RA), entered in clinical case …
metabolism. Nineteen patients with rheumatoid arthritis (RA), entered in clinical case …
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
S Mori, Y Ueki, Y Akeda, N Hirakata, M Oribe… - Annals of the …, 2013 - ard.bmj.com
Objectives We assessed the impact of tocilizumab (TCZ), a humanised monoclonal anti-
interleukin-6 receptor antibody, on antibody response following administration of the 23 …
interleukin-6 receptor antibody, on antibody response following administration of the 23 …
Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus
K Matsumoto, Y Sera, H Nakamura… - Metabolism-Clinical …, 2002 - metabolismjournal.com
If a strong association between intima-media thickness of the common carotid artery (CCA-
IMT) and ischemic stroke can be determined in diabetic subjects, it may be a useful predictor …
IMT) and ischemic stroke can be determined in diabetic subjects, it may be a useful predictor …
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four–month, phase …
D van der Heijde, V Strand, Y Tanaka… - Arthritis & …, 2019 - Wiley Online Library
Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).
The phase III, 24‐month, placebo‐controlled Oral Rheumatoid Arthritis (ORAL) Scan trial …
The phase III, 24‐month, placebo‐controlled Oral Rheumatoid Arthritis (ORAL) Scan trial …